TY - JOUR T1 - Omega-3 fatty acid supplements and cardiovascular disease JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 39 LP - 39 DO - 10.1136/dtb.2018.4.0606 VL - 56 IS - 4 A2 - , Y1 - 2018/04/01 UR - http://dtb.bmj.com/content/56/4/39.1.abstract N2 - A meta-analysis of large randomised trials has assessed the association of omega-3 fatty acid (eicosapentaenoic acid [EPA] and docosahexanoic acid [DHA]) supplement use with the risk of fatal and non-fatal cardiovascular heart disease (CHD) and major vascular events.1 The meta-analysis (10 trials; 77,917 high-risk people) included studies that involved at least 500 participants and ran for at least 1 year (mean duration 4.4 years).1 The main outcomes included fatal CHD, non-fatal myocardial infarction (MI), stroke, major vascular events and all-cause mortality, as … ER -